Regulatory Developments for Methylergonovine Maleate Signal Increased Competition in Uterotonics
Obstetrics · Uterotonics • Regulatory Approval • Jul 15, 2026
Assessment confidence: 72% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
Executive Thesis
The FDA's acceptance of Amneal Pharmaceuticals' supplemental application for Methylergonovine Maleate is a significant regulatory milestone that could strengthen Amneal's competitive position in the uterotonics market. This development necessitates close monitoring of market dynamics and competitor responses. Regulatory context from FDA (FDA AP — METHYLERGONOVINE MALEATE (SUPPL)) supports the near-term read. Assessment grounded in 15 ranked evidence items (9 high-relevance).
Strategic Assessment
Portfolio teams should assess the implications of this approval on market share and pricing strategies for uterotonics. The strongest clinical anchor is Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN (ClinicalTrials.gov), sponsor/company relevance (novartis). In Obstetrics · Uterotonics, 6 regulatory and 3 competitive items passed relevance filtering for Amneal Pharmaceuticals.
Competitive Pressure
The most relevant competitive pressure comes from FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Grants Priority Review for ZERBAXA Supplement by Cubist Pharmaceuticals. This approval could enhance Amneal's position in the uterotonics market, potentially impacting competitors with similar products.
Regulatory Outlook
Regulatory risk is concentrated around FDA AP — METHYLERGONOVINE MALEATE (SUPPL) (FDA). Entity match (methylergonovine maleate); Regulatory pathway relevance (nda). While the acceptance of the application is a positive step, the final approval and market launch will determine the full regulatory implications for Amneal and its competitors.
Key Risks
- Elevated medium regulatory exposure for Amneal Pharmaceuticals could delay market entry or constrain labeling if agency review intensifies.
Key Opportunities
- The approval may lead to increased market share for Amneal, potentially affecting pricing strategies and revenue for competitors in the uterotonics segment.
- Portfolio teams should assess the implications of this approval on market share and pricing strategies for uterotonics.
What Would Change This Assessment
- This becomes more urgent if Monitor for the official approval date and any subsequent market launch announcements.
- Timeline shift beyond mid term would change urgency.
- A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.
Supporting Evidence
FDA AP — METHYLERGONOVINE MALEATE (SUPPL)
FDAhigh relevance
Entity match (methylergonovine maleate); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — METHYLERGONOVINE MALEATE (SUPPL)
FDAhigh relevance
Entity match (methylergonovine maleate); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — BRIMONIDINE TARTRATE AND TIMOLOL MALEATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — BRIMONIDINE TARTRATE AND TIMOLOL MALEATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — FLUVOXAMINE MALEATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceRare Disease Drug Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View sourceStudy to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View sourceHydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceA Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
No evidence in this category.
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceRNA polymerase II phosphorylation dynamics: from molecular mechanisms to human disease.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Related Signals
- FDA Approval Update for Methylergomovine Maleate by Amneal Pharmaceuticals
Regulatory Approval
- FDA Grants AP Status for Methylergonovine Maleate ANDA211919
Regulatory Approval
Related Regulatory Precedents
FDA
Withdrawn | Cancer Accelerated Approvals
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have been subsequently withdrawn, and are therefore, no longer FDA-approved.
SourceFDA
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
SourceFDA
CDER proposes to withdraw approval of TAVNEOS
SourceFDA
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
SourceFDA
FDA TA — ANDA219207
Application ANDA219207. Sponsor: SHANGHAI AUCYUN PHARMACEUTICALS CO., LTD. Submission status: TA. Submission type: ORIG. Review priority: STANDARD.
Source